Raphael Pharmaceutical (RAPH) Net Income Growth (3y) (2023 - 2024)

Raphael Pharmaceutical (RAPH) Net Income Growth (3y) (2023 - 2024) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income Growth (3y) (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	14.04%
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-0.23%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-27.09%
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	8.71%
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	-34.81%
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	14.78%
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	36.74%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Raphael Pharmaceutical	28.25 Mn	28.25 Mn	-	21.98%

Download Data